3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Breast Neoplasms
132
Neoplasms
114
Prostatic Neoplasms
63
Lung Neoplasms
47
Head and Neck Neoplasms
46
Colorectal Neoplasms
35
Ovarian Neoplasms
33
Uterine Cervical Neoplasms
28
Endometrial Neoplasms
23
Motor Activity
22
Neoplasm Metastasis
20
Multiple Myeloma
19
Brain Neoplasms
19
Pancreatic Neoplasms
18
Rectal Neoplasms
17
Lymphoma
16
Fatigue
16
Carcinoma, Non-Small-Cell Lung
16
Pain
15
Gastrointestinal Neoplasms
15
Colonic Neoplasms
15
Leukemia
14
Depression
14
Oropharyngeal Neoplasms
13
Urinary Bladder Neoplasms
12
Melanoma
12
Hematologic Neoplasms
12
Esophageal Neoplasms
12
Anxiety Disorders
12
Stomach Neoplasms
11
Interventions
pembrolizumab
3
lenvatinib
3
gallium 68 PSMA-11
2
apatinib
2
Protons
2
Magnetic Resonance Spectroscopy
2
Imatinib Mesylate
2
Epirubicin
2
Cisplatin
2
Carboplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
tislelizumab
1
regorafenib
1
enfortumab vedotin
1
cabozantinib
1
avelumab
1
anlotinib
1
amivantamab
1
abemaciclib
1
Tretinoin
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sunitinib
1
Standard of Care
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Radiation
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Adenoid Cystic
×
Surveys and Questionnaires
×
Clear all
NCT06535997
2025-08-06
PRIMHADRON
Hospices Civils de Lyon
Completed
62 enrolled